Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed ...
ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based ...
3 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces further investment in virus-like particle ...
– No evidence of immune interference; initial indication of combinability achievable with company’s VLP technology – – Next steps: Icosavax plans to initiate a Phase 2 immunogenicity trial for IVX-A12 ...
VLP Law Group is a so-called virtual firm—meaning it has no office and minimal overhead—where all the work is corporate and almost all the lawyers are partners. The firm opened in 2008, just as the ...
Making machines respond in ways similar to humans has been a relentless goal of AI researchers. To enable machines to perceive and think, researchers propose a series of related tasks, such as face ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results